Highly Potent APIs Are Becoming More Potent And Complex
Source: Evonik Corporation

Dr. Andreas Meudt is the global head of Exclusive Synthesis for Evonik, one of the world’s top three CMOs for APIs and the largest for highly potent APIs (HPAPIs). In this interview, Dr. Meudt shares his thoughts on key growth trends for HPAPIs, and why more pharma companies are outsourcing their production to contract specialists.
access the Q&A!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
Evonik Corporation
This website uses cookies to ensure you get the best experience on our website. Learn more